Status: Not yet recruiting
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
This is a Phase 1, first in human, three-part randomized, double-blind, placebo-controlled dose escalation trial to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 following single ascending dose (SAD) and multiple ascending dose administration (MAD), and an optional food effect (FE) cohort in healthy volunteers. The study will be conducted at a single site. Approximately 40 subjects will be enrolled in SAD, 30 in MAD, and 8 in FE.
Participants needed: 70
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: EquilliumUpdated: Oct 9, 2026Locations: 1
Eligibility criteria
Males and females 18 to 65 years of age inclusive [+3]
History of chronic alcohol abuse or excessive alcohol intake [+8]